Polycyclic organic compounds, Heterocyclic compound, Psychoanaleptics, oakwoodchemical.com, Mood stabilizers, Heterocyclic compounds, Heterocyclic compounds (bridged-ring), Psychopharmacology

Lurasidone (trade name Latuda) is an atypical antipsychotic developed by Dainippon Sumitomo Pharma and marketed by Sunovion in the U.S. It has been an FDA approved treatment for schizophrenia since 2010 and for treating depressive episodes in adults with bipolar I disorder since 2013. It can be used alone or in combination with mood stabilizers such as lithium or valproate (e.g., Depakote).